Physician profile
Samra Khalid
NPI 1467795476
$6,653.57
in general payments reported to CMS, 2019-2025
30 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,153 · 2020: $12.20 · 2021: $423 · 2022: $778 · 2023: $3,810 · 2024: $317 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,250 · Food and Beverage: $947 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,250.00 |
| Food and Beverage | $946.81 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,250.00 | 2023 | Apretude |
| Celularity INC. | $914.00 | 2019 | |
| Abbvie INC. | $522.71 | 2019-2024 | |
| Astellas Pharma US INC | $254.93 | 2023-2024 | Veozah |
| Exeltis, USA INC. | $192.59 | 2020-2024 | Slynd, Tyblume |
| Coopersurgical, INC. | $180.25 | 2021-2025 | Paragard T 380a, Paragard T 380a, Wallach Cryosurgical Equipment |
| Agile Therapeutics, INC. | $162.94 | 2021-2024 | Twirla |
| Myovant Sciences INC. | $147.69 | 2022 | |
| Hologic Sales and Service, LLC | $142.82 | 2019-2025 | Myosure Tissue Removal Device, Acessa Provu System, Novasure |
| Sumitomo Pharma America, INC. | $116.63 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $74.99 | 2022-2024 | |
| Aspira Women'S Health INC | $71.66 | 2022 | |
| Amgen INC. | $70.28 | 2022-2023 | Prolia, Evenity |
| Avion Pharmaceuticals | $61.33 | 2021-2023 | Balcoltra |
| Therapeuticsmd, INC. | $59.29 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $58.30 | 2021-2022 | |
| Organon LLC | $53.26 | 2021-2025 | Nuvaring, Nexplanon |
| Millicent US INC | $47.24 | 2024-2025 | Femring, Intrarosa |
| Scynexis, INC. | $37.51 | 2022 | |
| Vertical Pharmaceuticals, LLC | $29.73 | 2019 | |
| Allergan, INC. | $28.91 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.82 | 2022 | |
| Becton, Dickinson and Company | $25.92 | 2023 | Bd Onclarity |
| Convatec INC. | $22.00 | 2022 | |
| Exact Sciences Corporation | $21.95 | 2023 | Cologuard Collection Kit |
| Pharmacosmos Therapeutics INC. | $20.53 | 2022 | |
| Minerva Surgical, INC | $16.42 | 2021 | |
| Amag Pharmaceuticals, INC. | $14.80 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.43 | 2021 | |
| Glaxosmithkline, LLC. | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samra Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.